Targeted nanomedicine in cisplatin-based cancer therapeutics

Ye, Han; Wen, Panyue; Li, Junjie; Kataoka, Kazunori

doi:10.1016/j.jconrel.2022.03.049

Cited by 62 publications

(45 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cisplatin (CDDP) is the first platinum drug approved by the US Food and Drug Administration in 1978, and the only platinum‐based anticancer drug included on the World Health Organization′s list of essential medicines. The CDDP‐based regimens have high efficiency in treating a wide range of solid tumors [4] . However, clinical trials have shown that CDDP exhibited high toxicity even at a low dosage with an extended treatment cycle [5] .…”

Section: Methodsmentioning

confidence: 99%

Spatiotemporally Targeted Polypeptide Nanoantidotes Improve Chemotherapy Tolerance of Cisplatin

Yang

Zou

et al. 2022

Angewandte Chemie

View full text Add to dashboard Cite

The toxicity of drugs causes various adverse effects in patients. While antidotes that neutralize drug toxicity help reduce systemic damage during clinical therapy, these antidotes are generally accompanied by the loss of drug efficacy. Herein, the spatiotemporally targeted polycystine‐based nanoantidotes were designed as a neutralizer of cisplatin (CDDP) to decrease its toxicity without affecting its anticancer efficacy. The nanoantidotes administered before CDDP selectively accumulated in the liver and kidney and then firmly bound to CDDP through the highly stable Pt−S bond during subsequent chemotherapy. This two‐step administration strategy reduced the level of Pt in normal organs, shortened the half‐life of CDDP in plasma, and increased the tolerance to CDDP. More importantly, the nanoantidotes maintained the anticancer efficacy of CDDP after reducing systemic toxicity, indicating its great potential in expanding the clinical application of CDDP.

show abstract

Section: Methodsmentioning

confidence: 99%

Spatiotemporally Targeted Polypeptide Nanoantidotes Improve Chemotherapy Tolerance of Cisplatin

Yang

Zou

et al. 2022

Angewandte Chemie

View full text Add to dashboard Cite

show abstract

“…As shown in Fig. 1 , and Tables 1 and 2 , many studies have already taken advantages of nanocarriers to improve the efficacy of CDDP and reduce their nephrotoxicity [ 20 ]. In this regard, the kidneys are responsible for filtering and removing molecules smaller than 6 nm from blood.…”

Section: Introductionmentioning

confidence: 99%

Ameliorative impacts of polymeric and metallic nanoparticles on cisplatin-induced nephrotoxicity: a 2011–2022 review

et al. 2022

View full text Add to dashboard Cite

Cisplatin (CDDP) is a well-known platinum-based drug used in the treatment of various malignancies. However, the widespread side effects that this drug leaves on normal tissues make its use limited. Since cisplatin is mainly eliminated from the kidneys, CDDP-induced nephrotoxicity is the most significant dose-limiting complication attributed to cisplatin, which often leads to dose withdrawal. Considering the high efficiency of cisplatin in chemotherapy, finding renoprotective drug delivery systems for this drug is a necessity. In this regard, we can take advantages of different nanoparticle-based approaches to deliver cisplatin into tumors either using passive targeting or using specific receptors. In an effort to find more effective cisplatin-based nano-drugs with less nephrotoxic effect, the current 2011–2022 review study was conducted to investigate some of the nanotechnology-based methods that have successfully been able to mitigate CDDP-induced nephrotoxicity. Accordingly, although cisplatin can cause renal failures through inducing mitochondria dysfunction, oxidative stress, lipid peroxidation and endoplasmic reticulum stress, some CDDP-based nano-carriers have been able to reverse a wide range of these advert effects. Based on the obtained results, it was found that the use of different metallic and polymeric nanoparticles can help renal cells to strengthen their antioxidant systems and stay alive through reducing CDDP-induced ROS generation, inhibiting apoptosis-related pathways and maintaining the integrity of the mitochondrial membrane. For example, nanocurcumin could inhibit oxidative stress and acting as a ROS scavenger. CONPs could reduce lipid peroxidation and pro-inflammatory cytokines. CDDP-loaded silver nanoparticles (AgNPs) could inhibit mitochondria-mediated apoptosis. In addition, tea polyphenol-functionalized SeNPs (Se@TE) NPs could mitigate the increased level of dephosphorylated AKT, phosphorylated p38 MAPK and phosphorylated c-Jun N-terminal kinase (JNK) induced by cisplatin. Moreover, exosomes mitigated cisplatin-induced renal damage through inhibiting Bcl2 and increasing Bim, Bid, Bax, cleaved caspase-9, and cleaved caspase-3. Hence, nanoparticle-based techniques are promising drug delivery systems for cisplatin so that some of them, such as lipoplatins and nanocurcumins, have even reached phases 1–3 trials.

show abstract

“…FU also has multiple applications and is one of the most beneficial drugs to date to treat breast, head, neck, anal, stomach, colon, and skin cancers [24]. Cisplatin, which is one of the most common anticancer chemotherapy drugs, is particularly effective in treatment of testis, ovary, esophageal, bladder, non-small-cell lung cancers, and head and neck malignancies [90,91]. Nedaplatin is also an antineoplastic drug which is used for cancer chemotherapy with the purpose to decrease the inherent toxicities induced by cisplatin [92].…”

Section: Introductionmentioning

confidence: 99%

Boron Clusters in Biomedical Applications: A Theoretical Viewpoint

Shakerzadeh¹,

Tahmasebi²,

Duong³

et al. 2022

Characteristics and Applications of Boron

View full text Add to dashboard Cite

In this chapter, we presented an analysis of the recent advances in the applications of boron clusters in biomedical fields such as the development of biosensors and drug delivery systems on the basis of quantum chemical calculations. Biosensors play an essential role in many sectors, e.g., law enforcement agencies for sensing illicit drugs, medical communities for detecting overdosed medications from human and animal bodies, etc. The drug delivery systems have theoretically been proposed for many years and subsequently implemented by experiments to deliver the drug to the targeted sites by reducing the harmful side effects significantly. Boron clusters form a rich and colorful family of atomic clusters due to their unconventional structures and bonding phenomena. Boron clusters and their complexes have various biological activities such as the drug delivery, imaging for diagnosis, treatment of cancer, and probe of protein-biomolecular interactions. For all of these reactivities, the interaction mechanisms and the corresponding energetics between biomaterials and boron clusters are of essential importance as a basic step in the understanding, and thereby design of relevant materials. During the past few years, attempts have been made to probe the nature of these interactions using quantum chemical calculations mainly with density functional theory (DFT) methods. This chapter provides a summary of the theoretical viewpoint on this issue.

show abstract

Targeted nanomedicine in cisplatin-based cancer therapeutics

Cited by 62 publications

References 105 publications

Spatiotemporally Targeted Polypeptide Nanoantidotes Improve Chemotherapy Tolerance of Cisplatin

Spatiotemporally Targeted Polypeptide Nanoantidotes Improve Chemotherapy Tolerance of Cisplatin

Ameliorative impacts of polymeric and metallic nanoparticles on cisplatin-induced nephrotoxicity: a 2011–2022 review

Boron Clusters in Biomedical Applications: A Theoretical Viewpoint

Contact Info

Product

Resources

About